Whalesbook
📉 The Financial Deep Dive
Poly Medicure Limited announced its Q3 FY26 results, showcasing a robust performance and a clear strategic pivot towards higher-value medical devices. The company reported consolidated revenue of INR 494 crore for the quarter ended December 31, 2025, marking a significant 16.4% year-on-year (YoY) increase and 11.2% quarter-on-quarter (QoQ) growth. Gross profit stood at INR 338 crore, with gross margins expanding by 300 basis points YoY to 68.4%. Operating EBITDA, excluding approximately INR 6-7 crore in acquisition-related costs, reached INR 119 crore, translating to an operating EBITDA margin of 24.2%. Profit After Tax (PAT) for the quarter was INR 71 crore, though this was impacted by INR 6.8 crore in one-time expenses related to labor code implementation and acquisition costs.
For the nine months ended December 2025 (9M FY26), consolidated revenue grew 9.1% YoY to INR 1,341 crore. Gross profit was INR 922 crore with gross margins at 68.8% (up 190 bps YoY). Operating EBITDA, after excluding INR 9.7 crore in acquisition costs, was INR 345 crore, with an operating EBITDA margin of 25.8%. This consolidated margin saw a slight decline from 27.4% YoY, attributed to the consolidation of recent acquisitions.
On a standalone basis, the company maintained strong profitability, with Q3 FY26 operating EBITDA at INR 112 crore and an EBITDA margin of 26.8%. The 9-month standalone EBITDA margin also stood at 26.6%, aligning with management's guidance.
🚀 Strategic Analysis & Impact
The core narrative emerging from the call is Poly Medicure's decisive shift from lower-technology products to high-complexity, high-growth medical devices. This strategic repositioning is bolstered by two key acquisitions – PendraCare and Citieffe Group – which are expected to enhance the company's European footprint and technological capabilities. Furthermore, the company secured crucial DCGI regulatory approval for next-generation cardiovascular products, including the Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB), for the Indian market. This move into advanced cardiology products signifies a step up the technology chain, targeting higher Average Selling Prices (ASPs) and creating significant entry barriers.
🚩 Risks & Outlook
Management has provided a positive outlook, forecasting overall revenue growth of approximately 20% for FY27, with the domestic business expected to expand around 25% and international business around 12-15%. They anticipate H2 FY26 revenue to be about 20% higher than H1 FY26. However, risks such as potential Chinese dumping of medical devices and trade-related disruptions remain pertinent. The integration of acquired entities and the successful commercialization of new, high-tech products will be critical for realizing projected growth and margin improvements. The company is also investing heavily in capacity expansion, with three new plants planned, requiring significant CapEx (INR 234 crore in 9M FY26). The long-term vision is to solidify Poly Medicure as a diversified medtech platform. Investors will closely watch the performance of the new product lines and the successful ramp-up of acquired entities.